The earnings call presented several positive developments, including significant revenue growth, reduced operating expenses, and progress in licensing and commercialization efforts across various segments. However, challenges such as a decline in cash position and uncertainties in revenue predictions were noted. Overall, the positive highlights outweigh the lowlights, indicating a promising outlook for the company.

Company Guidance -

Q2 2025

During VolitionRX Limited's First Quarter 2025 Earnings Conference Call, the company outlined significant financial progress and strategic goals for the year. Operating expenses were reduced by 35% compared to the first quarter of 2024, leading to a 48% decrease in net cash used in operating activities, which totaled $4.3 million. Revenue for the quarter was nearly $0.25 million, marking a 44% increase year-over-year, with the first revenue recorded from human product sales. Cash and cash equivalents were reported at $2.6 million. The company secured $2.3 million from a registered direct offering, $1.6 million in non-dilutive loan financing, and finalized a convertible loan note for $6.25 million for additional financial support. VolitionRX aims to achieve cash flow neutrality for the full year 2025 and is actively pursuing licensing discussions with over 10 companies, targeting a total addressable market of approximately $25 billion annually in cancer and sepsis diagnostics. The company is also making strides in the veterinary market and advancing its Nu.Q Discover program with collaborations in the pharmaceutical sector, which are expected to significantly contribute to revenue growth.

Significant Revenue Growth

VolitionRX reported a 44% increase in revenue compared to Q1 2024, including the first revenue recorded for sales of human products.

Operating Expenses Reduction

Total operating expenses for the quarter declined 35% compared to Q1 2024, reflecting cost reductions across all spending categories.

Successful Licensing Discussions

VolitionRX is in confidential discussions with over 10 companies to license their products, with seven companies having a combined market value exceeding $600 billion.

Nu.Q Platform Developments

The company is progressing in the commercialization of their Nu.Q platform in the human diagnostic market, with potential market opportunities in cancer and sepsis diagnostics.

First Revenue from CE Marked Product

VolitionRX recorded its first revenue from sales of its CE Marked Nu.Q NETs automated product in Europe.

Expansion of Nu.Q Vet

Nu.Q Vet Cancer Test is expanding its global reach, with significant partnerships in place to enhance canine cancer screening.

Nu.Q Discover Revenue Potential

Nu.Q Discover biomarkers are being utilized in a human clinical study sponsored by a leading pharmaceutical company, expected to generate significant revenue.

VolitionRX (VNRX) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

VNRX Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Aug 13, 2025	2025 (Q2)	-0.05 / -	-0.085	―	―	―
May 15, 2025	2025 (Q1)	- / -0.06	-0.1	40.00% (+0.04)	―
Mar 31, 2025	2024 (Q4)	-0.04 / -0.06	-0.1	40.00% (+0.04)	―
Nov 14, 2024	2024 (Q3)	-0.07 / -0.07	-0.11	36.36% (+0.04)	―
Aug 14, 2024	2024 (Q2)	-0.09 / -0.09	-0.14	39.29% (+0.06)	―
May 13, 2024	2024 (Q1)	-0.10 / -0.10	-0.15	33.33% (+0.05)	―
Mar 25, 2024	2023 (Q4)	-0.10 / -0.10	-0.13	23.08% (+0.03)	―
Nov 14, 2023	2023 (Q3)	-0.13 / -0.11	-0.14	21.43% (+0.03)	―
Aug 14, 2023	2023 (Q2)	-0.14 / -0.14	-0.14	0.00% (0.00)	―
May 10, 2023	2023 (Q1)	-0.14 / -0.15	-0.14	-7.14% (>-0.01)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

VNRX Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
May 15, 2025	$0.45	$0.43	-4.44%
Mar 31, 2025	$0.57	$0.52	-8.77%
Nov 14, 2024	$0.72	$0.68	-5.56%
Aug 14, 2024	$0.55	$0.57	+3.64%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does VolitionRX Ltd. (VNRX) report earnings?

VolitionRX Ltd. (VNRX) is schdueled to report earning on Aug 13, 2025, After Close (Confirmed).

What is VolitionRX Ltd. (VNRX) earnings time?

VolitionRX Ltd. (VNRX) earnings time is at Aug 13, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is VNRX EPS forecast?

VNRX EPS forecast for the fiscal quarter 2025 (Q2) is -0.05.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing